We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Inhibition of Nitric Oxide Production Raises Blood Pressure

By LabMedica International staff writers
Posted on 19 Jul 2010
Nitric oxide is a regulator of blood pressure, but the action of the protein thrombospondin-1 (TSP1) via its necessary receptor CD47, inhibits nitric oxide production and causes blood pressure to increase.

The interaction of nitric oxide with heme proteins causes a cascade of intracellular events that leads to specific physiological changes within cells. More...
For example, nitric oxide causes the smooth muscle cells surrounding blood vessels to relax, decreasing blood pressure. Nitric oxide plays an important role in the central and peripheral nervous systems; the overproduction of nitric oxide in brain tissues has been implicated in stroke and other neurological problems.

In the current study, investigators at the University of Pittsburgh School of Medicine (PA, USA; www.pitt.edu) tested the hypothesis that TSP1 inhibited NO formation by acting on the enzyme endothelial nitric oxide synthase (eNOS), which catalyzes the production of NO in the cells that line blood vessels.

They reported in the July 7, 2010, online edition of the journal Cardiovascular Research that TSP1, working through its receptor CD47, inhibited activation of eNOS, which in turn limited the production of NO, thus preventing blood vessels from relaxing and blood pressure from dropping. TSP1 was found to circulate in the blood stream at levels capable of inhibiting activation of eNOS and thus blocking NO production.

"For some time now, it has not been clear what role TSP1 served in the blood. Experiments in cells told us TSP1 could alter NO signaling. But TSP1 is a protein too large to cross through the endothelial layer and into the blood vessel wall, so it was not obvious how it could alter the muscle tone of the arteries,” said senior author Dr. Jeffrey S. Isenberg, professor of medicine at the University of Pittsburgh School of Medicine. "We also knew that mice genetically engineered to not produce TSP1 or CD47 showed more NO-based blood flow and blood vessel dilation. This suggested to us that perhaps circulating TSP1 was altering the ability of the endothelium to make NO by acting on eNOS.”

"Identifying and unraveling this important pathway for blood pressure regulation could lead to a better understanding of who will get high blood pressure and why, as well as allow us to develop better drugs to treat these patients,” said Dr. Isenberg. "Poorly controlled hypertension is a major risk factor for heart attacks and heart failure, stroke and kidney failure.”

The investigators are examining the possibility of developing a novel line of blood pressure-regulating drugs that would preserve eNOS activity by blocking the inhibitory action of TSP1 and CD47.

Related Links:

University of Pittsburgh School of Medicine




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.